Compare Etsy Inc (ETSY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Etsy Inc trades at $79.73 (market cap $7.38B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 11.3× Etsy Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Etsy Inc pays none. Which is the better fit depends on your goals.
| ETSY | REGN | |
|---|---|---|
Market Cap | $7.38B | $83.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $86.47 | $812.27 |
52-Week Low | $44.05 | $555.51 |
Enterprise Value | $9.33B | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $85.55, up 4.0% over 24 hours, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.98, exceeding expectations, and announced a $2 billion share repurchase program alongside a 12% workforce reduction to boost efficiency. Revenue growth remains stable at $2.9 billion for 2026, though net income margins have moderated from prior years.
Outlook is positive with raised 2026 guidance and AI-driven marketplace improvements, but risks include high debt levels and competitive pressures. Analysts are evenly split between Buy and Hold ratings, with a consensus price target of $85.71, suggesting limited near-term upside from current levels.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
